Total Payments
$216,817
2024 Payments
$8,082
Companies
18
Transactions
350
Medicare Patients
8,077
Medicare Billing
$1.1M
Payment Breakdown by Category
Other$199,331 (91.9%)
Food & Beverage$9,161 (4.2%)
Consulting$7,457 (3.4%)
Travel$835.79 (0.4%)
Education$32.33 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $199,331 | 92 | 91.9% |
| Food and Beverage | $9,161 | 237 | 4.2% |
| Consulting Fee | $7,457 | 13 | 3.4% |
| Travel and Lodging | $835.79 | 3 | 0.4% |
| Education | $32.33 | 5 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $86,823 | 79 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $52,618 | 45 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $34,702 | 27 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $33,073 | 108 | $0 (2024) |
| Lilly USA, LLC | $4,224 | 7 | $0 (2023) |
| Aralez Pharmaceuticals US Inc. | $3,724 | 8 | $0 (2017) |
| PFIZER INC. | $572.95 | 33 | $0 (2021) |
| Vifor Pharma, Inc. | $212.09 | 3 | $0 (2021) |
| iRhythm Technologies, Inc. | $192.03 | 12 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $156.78 | 7 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,082 | 9 | E.R. Squibb & Sons, L.L.C. ($5,150) |
| 2023 | $19,601 | 28 | Boehringer Ingelheim Pharmaceuticals, Inc. ($16,019) |
| 2022 | $16,876 | 28 | Boehringer Ingelheim Pharmaceuticals, Inc. ($14,622) |
| 2021 | $27,215 | 45 | Boehringer Ingelheim Pharmaceuticals, Inc. ($17,669) |
| 2020 | $27,022 | 45 | AstraZeneca Pharmaceuticals LP ($15,167) |
| 2019 | $30,268 | 74 | E.R. Squibb & Sons, L.L.C. ($10,872) |
| 2018 | $31,586 | 54 | Janssen Pharmaceuticals, Inc ($14,150) |
| 2017 | $56,167 | 67 | E.R. Squibb & Sons, L.L.C. ($21,698) |
All Payment Transactions
350 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/18/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $29.49 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 11/15/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $23.37 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/11/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Education | In-kind items and services | $9.09 | General |
| Category: Cardiovascular | ||||||
| 09/09/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,083.00 | General |
| Category: Cardiovascular | ||||||
| 08/21/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $28.19 | General |
| Category: Cardiovascular | ||||||
| 04/08/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,430.00 | General |
| Category: Cardiovascular | ||||||
| 03/25/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: Cardiovascular | ||||||
| 01/10/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $28.92 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,850.00 | General |
| Category: DIABETES | ||||||
| 12/19/2023 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,430.00 | General |
| Category: Cardiovascular | ||||||
| 12/11/2023 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $25.31 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/06/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: DIABETES | ||||||
| 12/04/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,850.00 | General |
| Category: DIABETES | ||||||
| 11/30/2023 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $29.17 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/29/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 11/29/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 11/15/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: DIABETES | ||||||
| 10/31/2023 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $260.00 | General |
| Category: Diabetes | ||||||
| 10/16/2023 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $23.76 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/19/2023 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $24.27 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/08/2023 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $23.25 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/08/2023 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $27.86 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/30/2023 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $23.55 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/20/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,850.00 | General |
| Category: DIABETES | ||||||
| 06/08/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: DIABETES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 1,938 | 3,132 | $941,960 | $282,444 |
| 2022 | 9 | 2,172 | 3,535 | $937,540 | $301,735 |
| 2021 | 9 | 2,144 | 3,317 | $736,499 | $283,565 |
| 2020 | 8 | 1,823 | 2,939 | $687,923 | $239,106 |
Total Patients
8,077
Total Services
12,923
Medicare Billing
$1.1M
Procedure Codes
53
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 292 | 1,059 | $360,840 | $114,254 | 31.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 329 | 462 | $198,730 | $54,949 | 27.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 266 | 287 | $148,690 | $44,284 | 29.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 169 | 243 | $105,650 | $29,431 | 27.9% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 214 | 225 | $74,150 | $23,464 | 31.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 45 | 45 | $25,330 | $7,030 | 27.8% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 400 | 528 | $10,560 | $3,756 | 35.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 20 | 20 | $10,980 | $2,825 | 25.7% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Office | 2023 | 164 | 222 | $4,440 | $1,574 | 35.4% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 13 | 15 | $900.00 | $311.10 | 34.6% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Facility | 2023 | 13 | 13 | $910.00 | $296.27 | 32.6% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Facility | 2023 | 13 | 13 | $780.00 | $269.62 | 34.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 281 | 1,084 | $314,360 | $104,439 | 33.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 331 | 474 | $199,850 | $61,494 | 30.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 271 | 313 | $178,410 | $57,977 | 32.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 150 | 218 | $91,780 | $28,134 | 30.7% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 227 | 253 | $75,900 | $25,058 | 33.0% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 212 | 280 | $25,170 | $8,250 | 32.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 46 | 47 | $25,380 | $7,049 | 27.8% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2022 | 428 | 572 | $11,440 | $4,303 | 37.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 11 | 11 | $5,940 | $1,936 | 32.6% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Office | 2022 | 148 | 210 | $4,200 | $1,546 | 36.8% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Facility | 2022 | 19 | 22 | $1,540 | $472.76 | 30.7% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Facility | 2022 | 22 | 23 | $1,610 | $415.26 | 25.8% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2022 | 13 | 14 | $980.00 | $346.00 | 35.3% |
About Dr. Joshua Kerstein, MD
Dr. Joshua Kerstein, MD is a Cardiovascular Disease healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1689632523.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joshua Kerstein, MD has received a total of $216,817 in payments from pharmaceutical and medical device companies, with $8,082 received in 2024. These payments were reported across 350 transactions from 18 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($199,331).
As a Medicare-enrolled provider, Kerstein has provided services to 8,077 Medicare beneficiaries, totaling 12,923 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Cardiovascular Disease
- Location Brooklyn, NY
- Active Since 05/02/2006
- Last Updated 12/17/2010
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1689632523
Products in Payments
- JARDIANCE (Drug) $78,851
- ELIQUIS (Drug) $44,869
- XARELTO (Drug) $34,702
- LOKELMA (Drug) $32,716
- PRADAXA (Drug) $12,196
- CAMZYOS (Drug) $7,639
- YOSPRALA (Drug) $3,724
- BRILINTA (Drug) $356.18
- Veltassa (Drug) $212.09
- ZIO Patch (Device) $192.03
- ENTRESTO (Drug) $156.78
- Repatha (Biological) $101.08
- Ambisome (Drug) $91.34
- Circulatory Support (Device) $78.03
- LifeVest (Device) $75.60
- CHANTIX (Drug) $70.33
- Corlanor (Drug) $39.73
- NORTHERA (Drug) $38.98
- Quadra Assura CRT Defibrillator (Device) $21.66
- BREO (Drug) $20.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Brooklyn
Dr. Felix Yang, M.d, M.D
Cardiovascular Disease — Payments: $599,451
Cardiovascular Disease $599,451
Ozgen Dogan, Md, MD
Cardiovascular Disease — Payments: $367,116
Cardiovascular Disease $367,116
Dr. Adam Budzikowski, M.d., Ph.d, M.D., PH.D
Cardiovascular Disease — Payments: $346,063
Cardiovascular Disease $346,063
Dr. Peter Rouvelas, M.d, M.D
Cardiovascular Disease — Payments: $339,378
Cardiovascular Disease $339,378
Dr. Ronald Wharton, M.d, M.D
Cardiovascular Disease — Payments: $298,083
Cardiovascular Disease $298,083
Dr. Sorin Brener, Md, MD
Cardiovascular Disease — Payments: $225,799
Cardiovascular Disease $225,799